mgalbrai, thanks for sharing links.
If i correctly understand, the problem, mentioned by Dr. Koretz, is that hcv treatment, from point of view of "evidence-based medicine", really, is a bit experimental treatment, like clinical trials... SVR is "unvalidated surrogate" and we cannot exclude that, in future, for example, new much more sensitive tests may be developed and all people with SVR may become "HCV-carriers", detected by those very sensitive tests...
There is another text about similar issues -
www.openhealthnews.com/story/2015-01-18/...is-c-drug-treatments
-The best evidence available suggests that most patients with hepatitis C will not go on to have severe complications of the disease (cirrhosis, liver failure, liver cancer), and hence could not benefit much from treatment.
-There is no evidence from randomized controlled trials that treatment prevents most of these severe complications
-There is no clear evidence that "sustained virologic response," (SVR), the surrogate outcome measure promoted by the pharmaceutical industry, means cure.
-While the new drugs are advertised as having fewer adverse effects than older drugs, it is not clear that their benefits, whatever they may be, outweigh their harms.
if these drugs have not been shown to do more good than harm, and the lack of evidence is clearly the responsibility of the drugs' manufacturers who chose not to do very large and/or long-term randomized controlled trials and not to assess clinical outcomes, what justification is there for the gargantuan prices of these drugs?
Possibly, it may have some consequences... For example, if we will make a strategy "to treat everyone hcv-infected as soon as possible" - what does it mean in terms of "evidence-based medicine"? Does it mean "to involve everyone of hcv-infected in a some sort of large uncontrolled "clinical trial"?
P.S. About tolerability of treatment - i know one guy, who tolerated high doses of interferon without significant problems, but, surprisingly, he did not tolerated several months of sofosbuvir.
He achieved SVR after discontinuation of sofosbuvir.